LearnGlossaryMarketStocksSuperinvestorsSign in

RGNX

REGENXBIO Inc.

Healthcare · $386M market cap

Verdict

We can't put a fair value on RGNX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth7.3% a year✗
Equity per share growth-11.7% a year✗
Sales growth-10.9% a year✗
Free cash flow growth13.8% a year✓
Return on invested capital-54.8%✗

Follow RGNX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Chan Mitchell

Chief Financial Officer · 2026-09-01

Tax withholding

$46K

Malzahn Craig

Chief Technology Officer · 2026-09-01

Tax withholding

$2K

About REGENXBIO Inc.

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works